Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States

D. Vanda, V. Canale, S. Chaumont-Dubel, R. Kurczab, G. Satała, P. Koczurkiewicz-Adamczyk, M. Krawczyk, W. Pietruś, K. Blicharz, E. Pękala, AJ. Bojarski, P. Popik, P. Marin, M. Soural, P. Zajdel

. 2021 ; 64 (2) : 1180-1196. [pub] 20210113

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21011573

Grant support
NV17-31834A MZ0 CEP Register

G-protein coupled receptors (GPCRs) exist in an equilibrium of multiple conformational states, including different active states, which depend on the nature of the bound ligand. In consequence, different conformational states can initiate specific signal transduction pathways. The study identified compound 7e, which acts as a potent 5-hydroxytryptamine type 6 receptor (5-HT6R) neutral antagonist at Gs and does not impact neurite growth (process controlled by Cdk5). MD simulations highlighted receptor conformational changes for 7e and inverse agonist PZ-1444. In cell-based assays, neutral antagonists of the 5-HT6R (7e and CPPQ), but not inverse agonists (SB-258585, intepirdine, PZ-1444), displayed glioprotective properties against 6-hydroxydopamine-induced and doxorubicin-induced cytotoxicity. These suggest that targeting the activated conformational state of the 5-HT6R with neutral antagonists implicates the protecting properties of astrocytes. Additionally, 7e prevented scopolamine-induced learning deficits in the novel object recognition test in rats. We propose 7e as a probe for further understanding of the functional outcomes of different states of the 5-HT6R.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011573
003      
CZ-PrNML
005      
20210507103247.0
007      
ta
008      
210420s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.0c02009 $2 doi
035    __
$a (PubMed)33439019
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vanda, David $u Faculty of Science, Department of Organic Chemistry, Palacký University, 17. listopadu 12, Olomouc 771 46, Czech Republic
245    10
$a Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States / $c D. Vanda, V. Canale, S. Chaumont-Dubel, R. Kurczab, G. Satała, P. Koczurkiewicz-Adamczyk, M. Krawczyk, W. Pietruś, K. Blicharz, E. Pękala, AJ. Bojarski, P. Popik, P. Marin, M. Soural, P. Zajdel
520    9_
$a G-protein coupled receptors (GPCRs) exist in an equilibrium of multiple conformational states, including different active states, which depend on the nature of the bound ligand. In consequence, different conformational states can initiate specific signal transduction pathways. The study identified compound 7e, which acts as a potent 5-hydroxytryptamine type 6 receptor (5-HT6R) neutral antagonist at Gs and does not impact neurite growth (process controlled by Cdk5). MD simulations highlighted receptor conformational changes for 7e and inverse agonist PZ-1444. In cell-based assays, neutral antagonists of the 5-HT6R (7e and CPPQ), but not inverse agonists (SB-258585, intepirdine, PZ-1444), displayed glioprotective properties against 6-hydroxydopamine-induced and doxorubicin-induced cytotoxicity. These suggest that targeting the activated conformational state of the 5-HT6R with neutral antagonists implicates the protecting properties of astrocytes. Additionally, 7e prevented scopolamine-induced learning deficits in the novel object recognition test in rats. We propose 7e as a probe for further understanding of the functional outcomes of different states of the 5-HT6R.
650    _2
$a zvířata $7 D000818
650    _2
$a astrocyty $x účinky léků $7 D001253
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x chemická syntéza $x farmakologie $7 D007093
650    _2
$a poruchy učení $x chemicky indukované $x prevence a kontrola $7 D007859
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a molekulární konformace $7 D008968
650    _2
$a neurity $x účinky léků $7 D016501
650    _2
$a neuroglie $x účinky léků $7 D009457
650    _2
$a neuroprotektivní látky $x chemická syntéza $x farmakologie $7 D018696
650    _2
$a pyridiny $x chemická syntéza $x farmakologie $7 D011725
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a receptory spřažené s G-proteiny $x účinky léků $7 D043562
650    _2
$a receptory serotoninové $x účinky léků $7 D011985
650    _2
$a antagonisté serotoninu $x chemická syntéza $x farmakologie $7 D012702
650    _2
$a agonisté serotoninových receptorů $x farmakologie $7 D017366
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Canale, Vittorio $u Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, Kraków 30-688, Poland
700    1_
$a Chaumont-Dubel, Severine $u Institut de Génomique Fonctionnelle, Univ. Montpellier, INSERM, CNRS, 141 Rue de la Cardonille, Montpellier 34-094, France
700    1_
$a Kurczab, Rafał $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Satała, Grzegorz $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Koczurkiewicz-Adamczyk, Paulina $u Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, Kraków 30-688, Poland
700    1_
$a Krawczyk, Martyna $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Pietruś, Wojciech $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Blicharz, Klaudia $u Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, Kraków 30-688, Poland
700    1_
$a Pękala, Elżbieta $u Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, Kraków 30-688, Poland
700    1_
$a Bojarski, Andrzej J $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Popik, Piotr $u Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków 31-343, Poland
700    1_
$a Marin, Philippe $u Institut de Génomique Fonctionnelle, Univ. Montpellier, INSERM, CNRS, 141 Rue de la Cardonille, Montpellier 34-094, France
700    1_
$a Soural, Miroslav $u Faculty of Science, Department of Organic Chemistry, Palacký University, 17. listopadu 12, Olomouc 771 46, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, Olomouc 779 00, Czech Republic
700    1_
$a Zajdel, Paweł $u Faculty of Pharmacy, Department of Organic Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, Kraków 30-688, Poland
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 2 (2021), s. 1180-1196
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33439019 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103246 $b ABA008
999    __
$a ok $b bmc $g 1650062 $s 1131952
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 2 $d 1180-1196 $e 20210113 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
GRA    __
$a NV17-31834A $p MZ0
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options